HC Wainwright Has Positive Outlook for AVDL Q1 Earnings

Key Points

• HC Wainwright has raised its Q1 2026 earnings estimate for Avadel Pharmaceuticals to $0.17 per share, up from a previous estimate of $0.13, while maintaining a "Buy" rating and a price target of $36.00.
• Avadel Pharmaceuticals recently reported Q2 earnings of $0.10 per share, significantly exceeding analysts' expectations of $0.02 and experiencing a robust revenue increase of 64.1% year-over-year.
• The stock currently holds a consensus rating of "Buy" with an average price target of $20.86, and notable recent ratings upgrades have come from firms including Wall Street Zen and UBS Group.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2026 earnings estimates for shares of Avadel Pharmaceuticals in a research note issued on Friday, September 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.17 for the quarter, up from their prior forecast of $0.13. HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals' Q2 2026 earnings at $0.19 EPS and Q4 2026 earnings at $0.26 EPS.

AVDL has been the topic of a number of other research reports. Wall Street Zen raised shares of Avadel Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Lifesci Capital raised shares of Avadel Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, September 3rd. UBS Group lifted their target price on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Wells Fargo & Company raised shares of Avadel Pharmaceuticals to a "hold" rating in a research note on Wednesday, September 3rd. Finally, Zacks Research raised shares of Avadel Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $20.86.

Avadel Pharmaceuticals Stock Up 5.1%

Shares of Avadel Pharmaceuticals stock opened at $15.76 on Monday. The firm has a market cap of $1.53 billion, a PE ratio of -525.33 and a beta of 1.57. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $16.66. The company's fifty day simple moving average is $12.00 and its two-hundred day simple moving average is $9.76.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million for the quarter, compared to analyst estimates of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The company's revenue was up 64.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.14) EPS. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Nisa Investment Advisors LLC lifted its position in Avadel Pharmaceuticals by 164.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $29,000 after acquiring an additional 2,055 shares during the period. Raymond James Financial Inc. purchased a new position in Avadel Pharmaceuticals during the 2nd quarter valued at about $65,000. Tower Research Capital LLC TRC lifted its position in Avadel Pharmaceuticals by 217.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company's stock valued at $78,000 after acquiring an additional 6,025 shares during the period. Exencial Wealth Advisors LLC purchased a new position in Avadel Pharmaceuticals during the 1st quarter valued at about $82,000. Finally, Thoroughbred Financial Services LLC purchased a new position in Avadel Pharmaceuticals during the 1st quarter valued at about $82,000. 69.19% of the stock is owned by hedge funds and other institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.